# SVRA catalysts: Savara Inc PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/svra/catalysts

> Savara Inc (SVRA) has 3 upcoming catalysts. The next is the Savara Inc PDUFA date, November 22, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for SVRA?

Savara Inc (SVRA) has 3 upcoming catalysts. The next is the Savara Inc PDUFA date, November 22, 2026. SEC Form 10-Q: "The FDA determined that the Company's responses to recent information requests by the Agency during its review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026." [Calendar and source filings](https://sec-api.dev/companies/svra/catalysts)

Source: SEC Form 10-Q, accession 0001193125-26-453535, https://www.sec.gov/Archives/edgar/data/1160308/000119312526453535/svra-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/companies/svra/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Savara Inc |
| Ticker | SVRA (Nasdaq) |
| SEC CIK | 1160308 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/svra |

## Cash runway

Cash $129.6M as of 2026-09-30; quarterly burn $42.5M; about 9.2 months of runway at that rate (XBRL company facts, accession 0001193125-26-453535).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2024 | [Savara Inc topline data readout](https://sec-api.dev/companies/svra/catalysts) | SVRA |  | completed, positive | "In June 2024, we announced positive top line results from the IMPALA-2 trial which enrolled 164 patients from 43 sites across 16 countries, making it the largest placebo-controlled trial conducted in autoimmune PAP." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1160308/000119312526105076/svra-20251231.htm)) |
| Mar 2025 | [Savara Inc topline data readout](https://sec-api.dev/companies/svra/catalysts) | SVRA |  | completed, positive | "Savara previously announced positive top-line results from the Phase 3 clinical trial and, in March 2025, complete the submission of the Biological License Application ("BLA") to the FDA for MOLBREEVI." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1160308/000095017025070283/svra-20250331.htm)) |
| October 29, 2025 | [Savara Inc FDA approval](https://sec-api.dev/companies/svra/catalysts) | SVRA |  | completed, approved | "LANGHORNE, PA - October 29, 2025 - Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced a $75 million royalty funding agreement with funds managed by RTW Investments, LP (RTW), subject to FDA approval of MOLBREEVI." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1160308/000119312525256290/d55049dex991.htm)) |
| November 22, 2026 | [Savara Inc PDUFA date](https://sec-api.dev/companies/svra/catalysts) | SVRA |  | scheduled | "The FDA determined that the Company's responses to recent information requests by the Agency during its review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1160308/000119312526453535/svra-20260930.htm)) |
| June 2027 | [Molgramostim primary completion](https://sec-api.dev/pdufa/molgramostim) | SVRA | Autoimmune Pulmonary Alveolar Proteinosis | scheduled | "NCT06431776 (Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Savara Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06431776)) |
| Jun to Sep 2027 | [Molgramostim topline data readout](https://sec-api.dev/pdufa/molgramostim) | SVRA | Autoimmune Pulmonary Alveolar Proteinosis | scheduled | "NCT06431776 (Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Savara Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06431776)) |

## Drugs

- [Molgramostim](https://sec-api.dev/pdufa/molgramostim): Autoimmune Pulmonary Alveolar Proteinosis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/svra/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SVRA catalysts: Savara Inc PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/svra/catalysts

```bibtex
@misc{secapidev_companies_svra_catalysts_20261116,
  title        = {SVRA catalysts: Savara Inc PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/svra/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_svra_catalysts_20261116","title":"SVRA catalysts: Savara Inc PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/svra/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
